An investigational new drug application from Q Therapeutics, Inc., to help treat amyotrophic lateral sclerosis (ALS) received approval for testing from the U.S. Food and Drug Administration (FDA).
Called Q-Cells, the cellular therapeutic product is made up of glial-restricted progenitor cells, or early descendants of neural stem cells that make up 50% of brain cells. Trials in animals with ALS and other central nervous system diseases showed the delivery of Q-Cells to the brain and spinal cord modified the diseases. With this FDA clearance, Q-Therapeutics can begin testing in humans.
“Every 90 minutes someone in the world is diagnosed with ALS, and current therapies offer little hope,” says James Campanelli, PhD, Vice President of Research and Development at Q Therapeutics. “With this FDA clearance, we are on the cusp of performing groundbreaking human studies with a cellular therapeutic that has the potential to change the outlook for people living with ALS and their loved ones.”
For more information, visit qthera.com.
(Register or login to add comments.)